Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAC vs VAC/VI Plus Maintenance in Intermediate-Risk Rhabdomyosarcoma
NCT07466316Phase 3Recruiting
- Sponsor
- Children's Oncology Group
- Start
- Jul 2026
- Primary completion
- Mar 2031
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Lipid-based Nanoparticles
- Countries
- 2
01
Overview
A Phase 3 trial of cyclophosphamide in rhabdomyosarcoma (RMS), sponsored by Children's Oncology Group. Started Jul 2026; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT07466316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07466316.